ConductScience.org, home

Disease · MONDO_0005352

conduct disorder

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. conduct disorder. Diseases, record MONDO_0005352. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005352

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
conduct disorder
Open Targets
Open Targets ID
MONDO_0005352
Open Targets
Other names
conduct dis
Open Targets
Disease Ontology
DOID:12995
Disease Ontology
MeSH
D019955
MeSH
NCI Thesaurus
C89329
NCI Thesaurus
Highest stage of its drugs
Approval, for 2 of its 7 drugs, from DailyMed
Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
CHLORPROMAZINECHEMBL71Small moleculeApprovalDailyMed100Drugs and targets
HALOPERIDOLCHEMBL54Small moleculeApprovalDailyMed100Drugs and targets
RISPERIDONECHEMBL85Small moleculePhase 3ClinicalTrials.gov333Drugs and targets
LITHIUM CARBONATECHEMBL1200826Small moleculePhase 3ClinicalTrials.gov110Drugs and targets
OXYTOCINCHEMBL395429ProteinPhase 2ClinicalTrials.gov111Drugs and targets
ZIPRASIDONE HYDROCHLORIDECHEMBL1375743Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
METHYLPHENIDATECHEMBL796Small moleculePhase 1/2ClinicalTrials.gov111Drugs and targets

Targets11

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
DRD2D(2) dopamine receptor4D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonistApprovalhttps://conductscience.org/library/genes/1813Drugs and targets
HTR2A5-hydroxytryptamine receptor 2A4Serotonin 2a (5-HT2a) receptor antagonistApprovalhttps://conductscience.org/library/genes/3356Drugs and targets
DRD3D2-like dopamine receptor2D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonistApprovalhttps://conductscience.org/library/genes/1814Drugs and targets
DRD4D2-like dopamine receptor2D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonistApprovalhttps://conductscience.org/library/genes/1815Drugs and targets
HTR2C5-hydroxytryptamine receptor 2C2Serotonin 2c (5-HT2c) receptor antagonistPhase 3https://conductscience.org/library/genes/3358Drugs and targets
GSK3AGlycogen synthase kinase-31Glycogen synthase kinase-3 inhibitorPhase 3https://conductscience.org/library/genes/2931Drugs and targets
GSK3BGlycogen synthase kinase-31Glycogen synthase kinase-3 inhibitorPhase 3https://conductscience.org/library/genes/2932Drugs and targets
IMPA1Inositol monophosphatase 11Inositol-1(or 4)-monophosphatase 1 inhibitorPhase 3https://conductscience.org/library/genes/3612Drugs and targets
OXTROxytocin receptor1Oxytocin receptor agonistPhase 2https://conductscience.org/library/genes/5021Drugs and targets
SLC6A2Sodium-dependent noradrenaline transporter1Norepinephrine transporter inhibitorPhase 1/2https://conductscience.org/library/genes/6530Drugs and targets

1 to 10 of 11

See all 11 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT02824627Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood DisordersPhase 2582022-08-30Mood Disorder, Disruptive Behavior DisordersOXYTOCINIts record names the diseaseClinicalTrials.gov
NCT00236470A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior DisordersPhase 3232Disruptive Behavior DisorderRISPERIDONEIts record names the diseaseClinicalTrials.gov
NCT00266552A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental RetardationPhase 3118Conduct Disorder, Disruptive Behavior Disorder, Oppositional Defiant DisorderRISPERIDONEIts record names the diseaseClinicalTrials.gov
NCT00250354
A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
Phase 3110Conduct Disorder, Oppositional Defiant Disorder, Disruptive Behavior DisorderRISPERIDONEIts record names the diseaseClinicalTrials.gov
NCT00676429Ziprasidone for Severe Conduct and Other Disruptive Behavior DisordersPhase 251Conduct Disorder, Oppositional Defiant DisorderZIPRASIDONE HYDROCHLORIDEIts record names the diseaseClinicalTrials.gov
NCT02247986Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral DisorderPhase 1/20Conduct Disorder, Attention Defict Hyperactivity DisorderMETHYLPHENIDATEIts record names the diseaseClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Oxytocin vs Placebo: deaths from any cause0 of 250 of 2752NCT02824627Trial comparisons
Oxytocin vs Placebo: serious adverse events0 of 250 of 2752NCT02824627Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
12218423RESULT1PubMed
12153826RESULT1PubMed
34288223DERIVED1PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005352

GET https://conductscience.org/api/diseases/v1/MONDO_0005352/drugs